These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36606529)

  • 21. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients.
    Hanifin J; Gupta AK; Rajagopalan R
    Br J Dermatol; 2002 Sep; 147(3):528-37. PubMed ID: 12207596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study.
    Fujimoto T; Terahara T; Okawa K; Inakura H; Hirayama Y; Yokozeki H
    J Dermatol; 2023 Nov; 50(11):1459-1472. PubMed ID: 37605375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study.
    Masur C; Soeberdt M; Kilic A; Knie U; Abels C
    Br J Dermatol; 2020 Jan; 182(1):229-231. PubMed ID: 31218668
    [No Abstract]   [Full Text] [Related]  

  • 24. Topical Botulinum Toxin Type A Liposomal Cream for Primary Axillary Hyperhidrosis: A Double-Blind, Randomized, Split-Site, Vehicle-Controlled Study.
    Lueangarun S; Sermsilp C; Tempark T
    Dermatol Surg; 2018 Aug; 44(8):1094-1101. PubMed ID: 29659406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
    Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F
    Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Lowe N; Naumann M; Eadie N
    Medicine (Baltimore); 2023 Jul; 102(S1):e32764. PubMed ID: 37499084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S; Yokozeki H
    J Dermatol; 2021 Aug; 48(8):1149-1161. PubMed ID: 34041788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of oral glycopyrronium bromide in hyperhidrosis.
    Bajaj V; Langtry JA
    Br J Dermatol; 2007 Jul; 157(1):118-21. PubMed ID: 17459043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Yokozeki H; Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S
    J Dermatol; 2021 Mar; 48(3):279-288. PubMed ID: 33410265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study.
    Heckmann M; Plewig G;
    Arch Dermatol; 2005 Oct; 141(10):1255-9. PubMed ID: 16230563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
    Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.
    Nguyen NV; Gralla J; Abbott J; Bruckner AL
    Pediatr Dermatol; 2018 Mar; 35(2):208-212. PubMed ID: 29334132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
    Naumann M; Lowe NJ; Kumar CR; Hamm H;
    Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
    Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
    J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
    Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
    BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study.
    Peserico A; Städtler G; Sebastian M; Fernandez RS; Vick K; Bieber T
    Br J Dermatol; 2008 Apr; 158(4):801-7. PubMed ID: 18284403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
    Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
    J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.